tbuckley/cabot-search huggingface dataset:
P129 Fungal contamination of valved holding chambers (VHCS): potential to prevent, and effect on drug delivery
Authors: MJ Sanders, R Bruin, CH Tran
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> Able Spacerâ−2 VHC (AS2) is one of many accessory devices available to improve pressurised metered dose inhaler (pMDI) drug delivery, but uniquely includes a ∼ 1wt% body polymer silver ion additive ( ∼ 1%Ag+) to combat microbial growth and reduce static. Drug-specific bacterial growth on VHC polymers<sup>1</sup> and the bacterial growth-reducing effects of the Ag+ polymer are known.<sup>2</sup> The fungal pathogen <i>Aspergillus fumigatus</i> causes serious pulmonary disease. We assessed the effect of 4%Ag+ on fungal activity and, subsequently, drug delivery characteristics. <h3>Methods</h3> Determination of fungal sporicidal activity was via modified ISO22196:2011 using flat body polymer discs (n = 3) of AS2 ∼ 1% Ag+ and AS2 4%Ag+, and sterile Control (same polymer minus Ag+, n = 6). 100mL <i>A. fumigatus</i> (5.0 x 10<sup>5</sup> spores/mL distilled water) was pipetted onto disc surfaces. Samples were incubated for 24 h at 35°C/ ≥ 95% relative humidity, with silver ions neutralised thereafter. Colony forming units (CFU) were enumerated by spiral dilution and converted to CFU/cm<sup>2</sup>. Aerosol performance of salbutamol (as salbutamol sulphate) pMDI (Ventolinâ Evohaler, GSK) through AS2 VHC ( ∼ 1% Ag+ as standard) and a newly-developed AS2 4% Ag+ VHC was assessed through a Next Generation Impactor (NGI) at 30 L/min. pMDIs and NGI were operated, and drug determinations made, using standard procedures. <h3>Results</h3> 24 h geometric mean Log<sub>10</sub><i>A. fumigatus</i> CFU/cm<sup>2</sup> were 4.2 × 10<sup>3</sup> (Control), 2.8 × 10<sup>3</sup> ( ∼ 1% Ag+), and 4.5 × 10<sup>2</sup> (4% Ag+), representing Log<sub>10</sub> and% reductions from Control of 0.2 (34%) and 1.0 (89%) for ∼1% Ag+ and 4% Ag+. Key salbutamol aerosol performance data were emitted dose (mg) 95.9 ± 11.0 and 94.9 ± 9.1; fine particle fraction (% &lt; 5.0 mm) 54.0 ± 4.3 and 53.6 ± 1.9; and fine particle dose (mg &lt; 5.0 mm) 52.0 ± 8.7 and 50.7 ± 3.8 for AS2 ∼ 1% Ag+ and AS2 4% Ag+ respectively. NGI recovery (Figure 1) profiles were very similar, including the VHC component: 38.9 ± 4.2 (AS2 ∼ 1% Ag+) and 40.2 ± 5.3 (AS2 4% Ag+). <h3>Conclusions</h3> Use of 4%Ag+ additive did not affect salbutamol aerosol performance and showed greater effect on <i>A. fumigatus</i> spored activity <i>in vitro</i>. VHC fungal <i>Candida</i> spp. and nebuliser <i>Aspergillus</i> spp. have been identified. The moist, anti-static setting of the Chamber may support and, of more concern, promote aerosolisation into the lungs of fungal material. Further research and understanding are necessary. <h3>Reference</h3> Sanders. <i>PCRM</i> 2016;<b>26</b>(16022):16. Sanders MJ, <i>et al</i>. P87 Klebsiella Pneumoniae Survival On Plastic Valved Holding Chamber Bodies. <i>Thorax</i> 2014;<b>69</b>(Suppl 2):A114.
S8 Osteopontin as an airway epithelial tumour promoter
Authors: I Psallidas, N Kanellakis, M Vreka, A Giannou, L Maniatis, C Moschos, I Giopanou, T Agalioti, I Lilis, S Magkouta, I Kalomenidis, NM Rahman, I Pavord, GT Stathopoulos
Journal: Thorax (2016)

Osteopontin (secreted phosphoprotein 1; SPP1) expression has been identified in human lung cancer and has been linked with enhanced tumour progression. To examine its functional role, we induced lung tumours by repetitive urethane or MCA/BHT lung carcinogens in C57BL/6 mice lacking both (<i>Spp1-/-</i>), one (<i>Spp1+/-</i>), or no (<i>Spp1+/+</i>) copy of the endogenous <i>Spp1</i> gene. Primary end-points were lung tumour number and size; secondary end-points were SPP1 expression, epithelial cell survival, carcinogen-induced inflammation, and angiogenesis. Data are presented as mean ± SD. Compared with <i>Spp1+/+</i> mice (n = 22), <i>Spp1-/-</i> mice (n = 25) developed dramatically fewer and significantly smaller lung tumours in response to urethane, while <i>Spp1±</i> mice (n = 12) behaved similar to <i>Spp1-/-</i> mice (number/diameter of lung tumours in <i>Spp1+/+</i>, <i>Spp1+/-</i>, and <i>Spp1-/-</i> mice, respectively: 16.1 ± 12.7/1.2 ± 0.3 mm, 2.4 ± 2.3/0.9 ± 0.2 mm, and 1.3 ± 1.6/0.7 ± 0.2 mm; P &lt; 0.05 for comparison of <i>Spp1+/+</i> with <i>Spp1-/-</i> and <i>Spp1+/-</i> mice). <i>Spp1-/-</i> mice were also protected from two-hit MCA/BHT-oncogenesis compared with <i>Spp1+/+</i> controls. <i>Spp1-/-</i> mice displayed decreased epithelial cell survival and reduced numbers of airspace macrophages early after urethane, and enhanced tumour cell apoptosis and limited tumour angiogenesis at late stages of lung tumour progression. SPP1 was expressed in the naïve lung by non-ciliated airway epithelial cells and alveolar macrophages and was significantly up-regulated during multi-stage lung carcinogenesis. Our data indicate that SPP1 is functionally involved in airway epithelial carcinogenesis and may present a target for lung cancer treatment and prevention.
S7 Mouse lung adenocarcinoma cell lines reveal PRL2C2 as a novel lung tumour promoter
Authors: NI Kanellakis, A Giannou, M Pepe, T Agalioti, D Zazara, M Vreka, I Lilis, I Giopanou, M Spella, A Marazioti, N Rahman, I Pavord, I Psallidas, GT Stathopoulos
Journal: Thorax (2016)

<h3>Background</h3> Carcinogen-inflicted human cancers, including lung tumours harbour thousands of mutations per genome, most of which are unknown (Garraway, LA <i>et al</i>, <i>Cell</i> 2013;153:17–37). <h3>Aim</h3> To develop a faithful mouse model of human tobacco carcinogen-induced lung adenocarcinoma suitable for the identification of novel oncogenic genes and pathways. <h3>Methods</h3> We repeatedly managed to obtain several murine lung adenocarcinoma cell lines (MLA) by chronically exposing various mouse strains to different tobacco carcinogens. MLA were characterised for cancer stemness and oncogenes, as well as global gene expression. <h3>Results</h3> To date, 12 MLA cell lines have been derived from <i>Wt</i> and transgenic mice on the <i>FVB</i>, <i>Balb/c</i>, and <i>C57BL/6</i> strains by means of urethane or diethylnitrosamine exposure. All MLA were immortal, phenotypically stable, and indefinitely passaged <i>in vitro</i> over a period of over 18 months and/or 60 passages. In addition, all cell lines were oncogenic, transplantable, metastatic, and uniformly lethal <i>in vivo</i>. Interestingly, MLA displayed <i>Kras</i> mutations in codon 61, mono- or bi-allelic <i>Trp53</i> loss, and expression of lung cancer stemness factors <i>Itgb3</i> and <i>Lgr6</i>, in amazing similarity to human lung cancers. Microarray revealed that all MLA cell lines heavily overexpressed <i>Prl2c2</i>, encoding proliferin, in comparison to the native lungs. <i>Prl2c2</i> silencing diminished MLA proliferation and stemness, to a degree comparable with <i>Itgb3</i> interference. <h3>Conclusions</h3> MLA are faithful models of human lung adenocarcinoma that led to the discovery of Prl2c2 as a candidate lung tumour promoter. <h3>Funding</h3> European Research Council Starting Independent Investigator Grant #260524. Respire 2 European Respiratory Society Fellowship, European Respiratory Society Short Term Research Fellowship.
Outcome of grade 3 and 4 cytopenia in newly diagnosed glioblastoma multiforme (GBM) patients treated with temozolomide (TMZ).
Authors: B. E. Sanchez, J. Munoz, H. Y. Ali, J. M. Anderson, P. Kuriakose
Journal: Journal of Clinical Oncology (2011)

2018 Background: Current standard treatment for GBM consists in radiotherapy (RT) plus concomitant and adjuvant (adj) TMZ. Myelosupression is the dose limiting toxicity of TMZ with grade 3 and 4 cytopenia occurring in ~16%. We describe the difference in outcome of newly diagnosed GBM patients treated with TMZ who developed grade 3 and 4 cytopenia. Methods: A 10-year retrospective analysis of newly diagnosed adult GBM patients (pts) treated with first-line TMZ. All pts received concurrent TMZ and RT with or without investigational drug. If the pt did not progress on magnetic resonance imaging (MRI) adj TMZ was given. Cytopenia events during TMZ therapy were graded using the National Cancer Institute Common Toxicity Criteria (v3). Survival distribution was estimated by the Kaplan-Meier method. Results: Of 191 pts, 23% developed grade 3 and 4 cytopenia. 74% pts were ≤ 65 years, 75% had 80-100% karnofsky performance status and 78% had surgical resection at diagnosis. 93% pts received 6 wks of concurrent RT 60 Gy and TMZ 75 mg/m2/d. The median dose of adj TMZ was 150-200 mg/m2/d1-d5 every 28d cycle. The median cycles was 4 (range, 0-24). The median progression free survival (PFS) was 6.7 months (mo). The 6 mo and 12 mo PFS for pts who had grade 3 and 4 cytopenia was 73% (95% confidence interval [CI], 57%-83%) and 33% (95% CI, 20%-47%); while in pts with no grade 3 and 4 cytopenia was 51% (95% CI, 43%-59%) and 24% (95% CI, 17.9%-31.8%). The unadjusted hazard ratio (HR) for death or disease progression of pts with grade 3 and 4 cytopenia, as compared to those without grade 3 and 4 cytopenia, was 0.58 [95% CI, 0.40 to 0.82; p< 0.003]. The HR for death or disease progression was 0.68 (95% CI, 0.47-0.98; p<0.045) among those with a methylated MGMT promoter. The total dose of TMZ was not different between both groups (p=0.284 by Wilcoxon rank sum test). Conclusions: Our study supports that newly diagnosed GBM pts who develop grade 3 and 4 cytopenia during TMZ therapy have improved PFS. Further clinical trials are required to validate grade 3 and 4 cytopenia as a potential biomarker for TMZ efficacy in an attempt to optimize and personalize GBM therapy.
High Dose Chemotherapy and Autologous Stem Cell Transplantation with Melphalan in Patients with Monoclonal Immunoglobulin Deposition Disease Associated with Multiple Myeloma.
Authors: Hani Hassoun, Brian T. Rafferty, Carlos Flombaum, Vivette D. D’Agati, Virginia M. Klimek, Adam Cohen, Adam Boruchov, Tarun Kewalramani, Lilian Reich, Heather Landau, Stephen D. Nimer, Raymond Comenzo
Journal: Blood (2007)
P2.06-017 Amethyst NSCLC Trial: Phase 2 Study of MGCD265 in Patients with Advanced or Metastatic NSCLC with Activating Genetic Alterations in MET
Authors: Lyudmila Bazhenova, Dong-Wan Kim, Luigi Cavanna, Ji-Youn Han, Jong Seok Lee, Hoon-Kyo Kim, Byoung Chul Cho, Marshall Schreeder, Ashiq Masood, Igor Rybkin, Melissa Johnson, Britt Boleman, Marta Batus, Estelamari Rodriguez, David Hong, Pasi Jänne, Raul Mena, Frederico Cappuzzo, Ivor Percent, Vanessa Tassell, James Christensen, Demiana Faltaos, Richard Chao, Hirak Der-Torossian, Diane Potvin, Ranee Mehra
Journal: Journal of Thoracic Oncology (2017)
Management of systemic anticancer treatment in patients (pts) under chronic dialysis: A raising concern and an emerging population—Preliminary results of the French CANDY (CANcer and DialYsis) study.
Authors: A. Thyss, N. Janus, V. Launay-Vacher, H. Boulanger, V. Roth, K. Maurizi, M. S. Islam, G. Deray, J. Durande, M. Ducret, L. Juillard, Z. Soltani, G. Motte, O. Moranne, J. Ferrero, J. Rottembourg, J. Thariat
Journal: Journal of Clinical Oncology (2011)

e13562 Background: 1 million people worldwide benefit from chronic dialysis with an increased rate in Western countries of 5% yearly. Significant improvements of chronic renal replacement therapy have led to prolonged survival. Due to mean age and heightened incidence of many cancers in dialyzed pts, the management of pts who suffer from both cancer and end-stage renal disease is challenging for oncologists and nephrologists. Specific questions were addressed to assess the efficacy/toxicity ratio, namely life expectancy, toxicity/dialysis clearance/optimal timing of chemotherapy. Methods: Retrospective multicentre review of dialysis centre charts for pts under dialysis who subsequently had a cancer. Results: Among 178 patients (66% male, median age 69) from 12 institutions, 35% were GU, 23% GI, lung 14%, hematologic 10%, head and neck 8%, or various others 10%. Most common histologies were adenocarcinomas 47%, of hematologic origin 17% and urothelial carcinomas 12%. Physical status was 0 48%, 1 18%, 2 30% and 3-4 4%. 36% had metastatic disease at diagnosis or diffuse hematologic malignancy. Median follow-up for living pts was 35 months and median survival 13 months. 32% were treated palliatively upfront: 21 for dialysis itself, 18 for cancer, 11 for age or other causes. Among 32% (N=57) treated with systemic treatment (carboplatin, fluorouracil, gemcitabine, cyclophosphamide, doxorubicin, melphalan, oxaliplatin, bortezomib), anti-cancer drugs ended prematurely, mostly for toxicity and/or death (78%). 72% of treated pts received at least one drug needing dosage adjustment and 82% at least one drug to be administered after dialysis sessions [www.siteGPR.com]. Overall, 88% of pts receiving anti-cancer drugs needed specific drug management because of dialysis. Conclusions: Survival was poor. Chemotherapy was indeed omitted or prematurely stopped in many cases. Specific scales are needed to select dialyzed pts for cancer treatment. Currently available specific drug management recommendations (dosage, timing) are being completed based on CANDY. Supported by an unrestricted educational grant from Amgen.
M1 Macrophages Eliminate Lymphoma Cells Through the Vitamin D Dependent Antimicrobial Peptide Cathelicidin
Authors: Heiko Bruns, Mario Fabri, Anna Maurberger, Shirin Pasemann, Cornelia Fahrenwaldt, Andrea Wilke, Stefanie Moi, Heidi Daudt, Kerstin Amann, Maike Büttner, Udo Gaipl, Andreas Mackensen, Armin Gerbitz
Journal: Blood (2011)
Loss of Platelet Membrane Phospholipid Asymmetry in Systemic Lupus Erythematosus: Association with Disease Activity and Hypercoagulable State.
Authors: Jaime Pereira, Teresa Quiroga, Loreto Massardo, Carol Pérez, Gino Alfaro, Mauricio Ocqueteau, Olga Panes, Diego Mezzano
Journal: Blood (2004)
P2.03a-003 Belinostat in Combination with Carboplatin and Paclitaxel in Patients with Chemotherapy-Naive Metastatic Lung Cancer (NSCLC)
Authors: Saiama Waqar, Sant Chawla, Brian Mathews, Dorothy Park, Tao Song, Mi Rim Choi, Thomas Niederman, Ramaswamy Govindan
Journal: Journal of Thoracic Oncology (2017)
Pleiotrophin Signaling Is Necessary and Sufficient for Hematopoietic Stem Cell Self-Renewal In Vivo
Authors: Heather A Himburg, Pamela Daher, J. Lauren Russell, Phuong Doan, Mamle Quarmyne, Sarah K. Meadows, Katherine Helms, Gonzalo Herradon, Nelson J. Chao, John P. Chute
Journal: Blood (2010)
Stem Cell Factor (SCF) for Hematopoietic Stem Cell (HSC) Mobilization: Results of the Randomized IFM 99-01 Trial.
Authors: Philippe Bourin, Anne Huynh, Christian Recher, Christian Berthou, Laurent Garderet, Lofti Benbouker, Anne-Marie Perry, Thierry Facon, Cyrille Hulin, Jean-Jacques Sotto, Laurent Voillat, Mauricette Michallet, Michel Attal
Journal: Blood (2004)
Gynaecologist is struck off for lying about indemnity cover
Authors: Clare Dyer
Journal: BMJ (2017)

A consultant gynaecologist whose former patients have made 85 legal claims against NHS trusts has been struck off the UK medical register for conducting private practice for nearly four and a half years without indemnity cover and lying about it.

Rod Irvine, 63, worked as a consultant with the now defunct South London Healthcare NHS Trust. The General Medical Council received a string of patient complaints about him from 2011 to 2014, the first of which came from a private patient who wished to sue Irvine and told the GMC that he had no indemnity cover.

On 20 occasions the GMC asked Irvine for an employer disclosure form listing his jobs and cover …
OA13.02 Phase II Trial of Pembrolizumab in Patients with Malignant Mesothelioma (MM): Interim Analysis
Authors: Hedy Kindler, Theodore Karrison, Yi-Hung Carol Tan, Buerkley Rose, Mehwish Ahmad, Christopher Straus, Robert Sargis, Tanguy Seiwert
Journal: Journal of Thoracic Oncology (2017)
PUB032 Surgical Management of cN1 Non-Small Cell Lung Cancer: Histological Impact on Nodal Status and Survival Outcomes
Authors: Tetsuya Mizuno, Shozo Sakata, Katsutoshi Seto, Hitoshi Dejima, Yasushi Yatabe, Hiroaki Kuroda, Noriaki Sakakura, Yukinori Sakao
Journal: Journal of Thoracic Oncology (2017)
Depsipeptide (FK228) Preferentially Induces Apoptosis in BCR/ABL-Expressing TF-1 Cells.
Authors: Seiichi Okabe, Tetsuzo Tauchi, Akihiro Nakajima, Goro Sashida, Masahiko Sumi, Akihiko Gotoh, Hal E. Broxmeyer, Junko H. Ohyashiki, Kazuma Ohyashiki
Journal: Blood (2005)
Complete Eradication of Minimal Residual Disease (MRD) in Patients with Hairy Cell Leukemia (HCL) after Cladribine (2CDA) Followed by an Extended Course of Rituximab.
Authors: Farhad Ravandi-Kashani, Susan O’Brien, Keating Michael, Dan Jones, Stefan Faderl, Alessandra Ferrajoli, William Wierda, Shirley Odinga, Sherry Pierce, Charles Koller, Srdan Verstovsek, Jeffrey Jorgensen, Hagop Kantarjian
Journal: Blood (2005)
P2.03b-063 Molecular Profiling in Advanced Non-Small-Cell Lung Cancer: Preliminary Data of an Italian Observational Prospective Study
Authors: Elisa Gobbini, Vanesa Gregorc, Domenico Galetta, Ferdinando Riccardi, Paola Bordi, Vieri Scotti, Anna Ceribelli, Lucio Buffoni, Evaristo Maiello, Angelo Delmonte, Tindara Franchina, Maria Rita Migliorino, Diego Cortinovis, Salvatore Pisconti, Massimo Di Maio, Paolo Graziano, Emilio Bria, Giulio Rossi, Antonio Rossi, Giulia Pasello, Concetta Sergi, Olga Martelli, Saverio Cinieri, Alice Lunghi, Silvia Novello
Journal: Journal of Thoracic Oncology (2017)
P3.02b-013 Evaluation of Lung Specific GPA Score in Adenocarcinoma Patients with Brain Metastasis and EGFR Activating Mutation
Authors: William Kao, Audrey Dugué, Pascal Dô, Catherine Dubos, Delphine Lerouge, Serge Danhier, Nicolas Richard, Radj Gervais
Journal: Journal of Thoracic Oncology (2017)
P3.02a-019 Real World Utilization and Outcomes of ALK-Positive Crizotinib Treated Metastatic NSCLC Patients in US Community Oncology Practice
Authors: Craig Reynolds, Elizabeth Masters, Jenny Black-Shinn, Jack Mardekian, Janet Espirito, Marley Boyd, Marc Chioda
Journal: Journal of Thoracic Oncology (2017)
P2.02-060 SBRT and Sequential Chemotherapy for Stage IIA to IIIA Non-Small Cell Lung Cancer - A Phase I Dose Escalation Study
Authors: Donata Von Reibnitz, Jamie Chaft, Abraham Wu, Daphna Gelblum, Ellen Yorke, Emliy Gelb, Sandra Mitchell, Kenneth Ng, Andreas Rimner
Journal: Journal of Thoracic Oncology (2017)
R-Flurbiprofen, a Non-Steroidal Anti-Inflammatory Agent (NSAID) with Anti-Tumor Activity, Inhibits the Stromal-Induced Upregulation of Interleukin-8 in Chronic Lymphocytic Leukemia Cells.
Authors: Michael B. Lilly, Jesus Berdeja, C.S. Chen, Svetlana Bashkyrova, Marina Zemskova
Journal: Blood (2004)
Abstract B28: Induced expression of Sprouty4 in breast invasive ductal carcinoma cells inhibits ERK MAP kinase and reduces malignant phenotype
Authors: Ryan M. Jackson, Ethan J. Brock, Seema Shah, Mansoureh Sameni, Bonnie F. Sloane, Quanwen Li, Raymond R. Mattingly
Journal: Clinical Cancer Research (2017)

Abstract Our previous work has identified increased expression of Sprouty4 in 3D models of breast ductal carcinoma in situ (DCIS). Sprouty4 in other systems has been shown to function as a negative regulator of the mitogen activated protein kinase (MAPK/ERK) pathway. We hypothesize that Sprouty4 is an endogenous inhibitor of ERK/MAPK signaling in DCIS, and that its loss or reduced expression is one mechanism by which triple-negative lesions progress toward invasive ductal carcinoma (IDC). Using immunohistochemistry our labs have found that Sprouty4 was highly expressed in some human premalignant breast tissue samples, and that this expression was reduced in malignant triple-negative samples. These results correspond with immunoblot data from our 3D culture model of breast cancer progression in which Sprouty4 expression was higher during DCIS than in the IDC stage. Efficient over-expression of Sprouty4 reduced both MAPK/ERK activity as well as the aggressive phenotype of MCF10.CA1d IDC cells. Immunofluorescence experiments done in IDC cells overexpressing Sprouty4 revealed relocation of E-cadherin back to the cell surface and the restoration of adherens junctions. To determine if these effects were due to changes in MAPK/ERK signaling, IDC cells were treated with MEK162, an allosteric MEK inhibitor. Nanomolar concentrations of drug restored an epithelial-like phenotype similar to that produced by Sprouty4 over-expression. From these data we conclude that Sprouty4 may act to control MAPK/ERK signaling in a subset of DCIS, thus limiting the progression of these premalignant breast cancers. Further, if in vivo data correspond with our in vitro work, this may argue for the investigation of MEK inhibitors as an adjunct treatment in triple-negative disease, where options are limited. Citation Format: Ryan M. Jackson, Ethan J. Brock, Seema Shah, Mansoureh Sameni, Bonnie F. Sloane, Quanwen Li, Raymond R. Mattingly. Induced expression of Sprouty4 in breast invasive ductal carcinoma cells inhibits ERK MAP kinase and reduces malignant phenotype. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr B28.
Manufacturing Babies and Public Consent: Debating the New Reproductive Technologies
Authors: J. Roberts
Journal: BMJ (1995)

Jose Van Dyck Macmillan, £12.99, pp 238 ISBN 0 333 62965 5

Reproductive technology is a growth industry. Since the birth of Louise Brown, the first child conceived by in vitro fertilisation techniques, in 1978, an entire medical specialty has developed to treat the “epidemic of infertility.” Just how this epidemic evolved, and specifically the parts played by the mutually suspicious professions of medicine and journalism, is the focus of Jose Van Dyck's Manufacturing Babies and Public Consent.

Social institutions do not live in isolation, Van Dyck argues. The boundaries of medicine, the mass media, and even fiction overlap and affect each other continuously. Because these relations …
Is First Line Single Agent Rituximab the Best Treatment for Indolent Non-Hodgkin’s Lymphoma? Update of a Multicentric Study Comparing Rituximab vs CNOP vs Rituximab Plus CNOP.
Authors: Silvia Rivas-Vera, Enrique Baez, Pedro Sobrevilla-Calvo, Severiano Baltazar, Francisco Tripp, Jorge Vela, Oscar Garces, Luis Aguilar, Gregorio Ignacio, Jorge Duque, Petty Rodriguez, Gustavo Reyes
Journal: Blood (2005)
The NHS in 2017
Authors: Fiona Godlee
Journal: BMJ (2017)

In 2008, when the NHS turned 60, a BMJ series concluded, “The most thoughtful birthday present the NHS could receive would be an extended period of calm before the next round of reforms is unleashed” (doi:10.1136/bmj.a524). Sadly, this isn’t what happened. Instead, as Sarah Wollaston, chair of the UK parliament’s health select committee, writes this week, the incoming coalition government imposed a disruptive, demoralising, and distracting reorganisation at a time of economic crisis and rapidly rising demand (doi:10.1136/bmj.j5). Rather than integrating health and social …
P1.02-027 A Comparative Analysis of Different Cytological Samples for the Assessment of ALK Gene Rearrangements in NSCLC Patients
Authors: Maria Lozano Escario, Luis Mejias, Marta Abengozar, Tania Labiano, Jose Subtil, Alfonso Gurpide, Mercedes Aguirre, Nerea Gomez, Maria Eugenia Echarri, M Amada Maset, Jorge Arabe, Pablo Panadero, Jose Paricio, Miguel Idoate, Jose Echeveste
Journal: Journal of Thoracic Oncology (2017)
Peptide Vaccination Induces Dynamic Changes in CD4+ and CD8+ T Cell Subsets: Report on the First Peptide Vaccination Trial in Patients with Chronic Lymphocytic Leukemia (CLL)
Authors: Krzysztof Giannopoulos, Malgorzata Kowal, Anna Dmoszynska, Jacek Rolinski, Kamila Mazurek, Jochen Greiner, Markus Rojewski, Stephan Stilgenbauer, Hartmut Döhner, Michael Schmitt
Journal: Blood (2008)
Evaluation of Pre-Transplantation T-Cell Receptor Excision Circles (TREC) in Reduced-Intensity Stem Cell Transplantation (RIST) Recipients.
Authors: Yuriko Morita-Hoshi, Yuji Heike, Shizuka Yamagata, Kinuko Tajima, Shuichi Taniguchi, Kensei Tobinai, Yoichi Takaue
Journal: Blood (2006)